Discovering and bringing one new drug to the public typically costs a pharmaceutical or biotechnology company up to $800 million and takes an average of 10 to 12 years. In this intensely competitive industry, companies continually seek out new software technologies and information resources to accelerate and streamline their drug-discovery activities. From rapid means to identify new drug candidates to computational toxicology to assist in screening drug candidates, GGA has developed critical high-end applications, as well as comprehensive databases with tools for information mining to service the pharmaceuticals/biotechnology industry.
For an analytical software company, GGA developed a series of innovative algorithms that allow for the identification of target signals in the presence of high noise levels, and built a complete data analysis software product for mass spectrometry data based on these algorithms. This product allows analytical chemists to perform analyses five to seven times faster than the rate achievable by conventional analytical methods when analyzing the purity of a drug.
Also, for various clients, GGA has developed more than 40 commercial software packages, including advanced tools for statistical analysis, interactive molecular model development, data manipulation, and 3-D visualization of complex molecules. One of these packages received the prestigious Reader's Choice Award from Scientific Computing & Instrumentation magazine three times.
The molecular modeling software that GGA developed is designed to provide quick and easy access to quantitative information about molecules, including their bioactivity and other properties. The program allows users to import data on tens of thousands of molecules and to examine the molecules using quantitative-structure-activity/property relationship (QSAR/QSPR) analysis. The system's built-in statistical routines include Genetic Algorithm Analysis, Partial Least Squares, Multi-Linear Regression, Principal Component Analysis, and Cluster Analysis.